Nanologica
Nanologica: Set up for Growth (Redeye)

2021-03-01 07:10
Redeye views the year-end report as another positive step in the commercialization process. The past year has been heavily affected by the pandemic; however, there has been considerable progress on many fronts. We believe that the company has reached a growth inflection point. The estimates for the current year are unchanged apart from some issues of inventory change and activated costs. We roll our model forward another year with a positive effect on the fair value in our DCF model. We raise our motivated value in our base case in our model to SEK 20(17) per share with a range from SEK 8(7) and 28(25) per share in the bear and bull case.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Nanologica - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -